DocMorris AG (ZRSEF)
USD 21.6
(-40.36%)
USD 21.6
(-40.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 82.28 Million CHF | 148.08% |
| 2022 | -171.11 Million CHF | 24.2% |
| 2021 | -225.73 Million CHF | -66.35% |
| 2020 | -135.69 Million CHF | -159.17% |
| 2019 | -52.35 Million CHF | -34.35% |
| 2018 | -38.97 Million CHF | -7.54% |
| 2017 | -36.23 Million CHF | -183.8% |
| 2016 | -12.76 Million CHF | -470.65% |
| 2015 | 3.44 Million CHF | -51.85% |
| 2014 | 7.15 Million CHF | 146.26% |
| 2013 | -15.46 Million CHF | -351.77% |
| 2012 | 6.14 Million CHF | -29.19% |
| 2011 | 8.67 Million CHF | 121.22% |
| 2010 | 3.92 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -18.96 Million CHF | 0.0% |
| 2024 Q1 | -18.96 Million CHF | 68.03% |
| 2023 Q3 | -29.66 Million CHF | 45.4% |
| 2023 Q2 | -54.32 Million CHF | -86.55% |
| 2023 FY | 82.28 Million CHF | 148.08% |
| 2023 Q1 | -29.12 Million CHF | 65.75% |
| 2023 Q4 | -59.32 Million CHF | -100.0% |
| 2022 Q3 | -43.76 Million CHF | 49.16% |
| 2022 FY | -171.11 Million CHF | 24.2% |
| 2022 Q1 | -41.78 Million CHF | 71.9% |
| 2022 Q2 | -86.08 Million CHF | -106.02% |
| 2022 Q4 | -85.02 Million CHF | -94.26% |
| 2021 Q2 | -77.03 Million CHF | -100.0% |
| 2021 FY | -225.73 Million CHF | -66.35% |
| 2021 Q1 | -38.51 Million CHF | 53.76% |
| 2021 Q4 | -148.7 Million CHF | -100.0% |
| 2021 Q3 | -74.35 Million CHF | 3.48% |
| 2020 Q3 | -41.65 Million CHF | 20.49% |
| 2020 FY | -135.69 Million CHF | -159.17% |
| 2020 Q4 | -83.3 Million CHF | -100.0% |
| 2020 Q2 | -52.38 Million CHF | -100.0% |
| 2020 Q1 | -26.19 Million CHF | 25.71% |
| 2019 FY | -52.35 Million CHF | -34.35% |
| 2019 Q1 | -8.55 Million CHF | 20.3% |
| 2019 Q2 | -17.1 Million CHF | -100.0% |
| 2019 Q4 | -35.25 Million CHF | -100.0% |
| 2019 Q3 | -17.62 Million CHF | -3.08% |
| 2018 Q2 | -8.75 Million CHF | 0.0% |
| 2018 FY | -38.97 Million CHF | -7.54% |
| 2018 Q1 | -8.75 Million CHF | 3.56% |
| 2018 Q4 | -10.72 Million CHF | 0.0% |
| 2018 Q3 | -10.72 Million CHF | -22.53% |
| 2017 Q2 | -8.62 Million CHF | 8.74% |
| 2017 Q1 | -9.45 Million CHF | -46.28% |
| 2017 FY | -36.23 Million CHF | -183.8% |
| 2017 Q4 | -9.08 Million CHF | 0.0% |
| 2017 Q3 | -9.08 Million CHF | -5.26% |
| 2016 Q4 | -6.46 Million CHF | 0.0% |
| 2016 Q3 | -6.46 Million CHF | -741.66% |
| 2016 Q2 | 1 Million CHF | 218.05% |
| 2016 Q1 | -853 Thousand CHF | -131.12% |
| 2016 FY | -12.76 Million CHF | -470.65% |
| 2015 Q1 | -1.01 Million CHF | -128.89% |
| 2015 Q4 | 2.74 Million CHF | 0.0% |
| 2015 Q3 | 2.74 Million CHF | 369.12% |
| 2015 FY | 3.44 Million CHF | -51.85% |
| 2015 Q2 | -1.01 Million CHF | 0.0% |
| 2014 Q2 | 52 Thousand CHF | 0.0% |
| 2014 Q1 | 52 Thousand CHF | 100.81% |
| 2014 Q4 | 3.52 Million CHF | 0.0% |
| 2014 FY | 7.15 Million CHF | 146.26% |
| 2014 Q3 | 3.52 Million CHF | 6678.85% |
| 2013 Q2 | -1.33 Million CHF | 0.0% |
| 2013 Q3 | -6.39 Million CHF | -378.74% |
| 2013 Q4 | -6.39 Million CHF | 0.0% |
| 2013 FY | -15.46 Million CHF | -351.77% |
| 2013 Q1 | -1.33 Million CHF | 0.0% |
| 2012 FY | 6.14 Million CHF | -29.19% |
| 2011 FY | 8.67 Million CHF | 121.22% |
| 2010 FY | 3.92 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alternative Energy Partners, Inc. | -3703.18 USD | 2221974.173% |
| Allstar Health Brands, Inc. | -499.34 Thousand USD | 16577.652% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | 69.18 Million USD | -18.925% |
| Café Serendipity Holdings, Inc. | -750.15 Thousand USD | 11068.371% |
| Decision Diagnostics Corp. | - USD | -Infinity% |
| Health Advance Inc. | -49.02 Thousand USD | 167943.009% |
| HealthWarehouse.com, Inc. | -1.77 Million USD | 4739.204% |
| LIGAND PHARMACEUTICAL INC | 52.15 Million USD | -57.764% |
| MedGen, Inc. | -15.54 USD | 529472429.472% |
| Omni Health, Inc. | 1.26 Million USD | -6401.064% |
| Oxford Investments Holdings Inc. | -299.1 Thousand USD | 27608.918% |
| Pineapple, Inc. | -1.47 Million USD | 5668.354% |
| ScripsAmerica, Inc. | -4.73 Million USD | 1839.15% |